Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigen.

PLoS One · 2025 · PMC11913275 · PMID 40096254

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Similarly to PSMA-targeted immunotherapeutic strategies, PSMA-radioligand therapy using PSMA-specific antibody loaded with Lutetium-177 (177Lu-J591) was associated with a highly significant decrease in prostate-specific antigen (PSA) levels in metastatic castration-resistant prostate cancer (mCRPC) patients [ 44 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.